123663-49-0 | Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-

Packsize	Purity	Availability	Price	Discounted Price
5mg	99%(HPLC)	in stock	$36.00	$25.00
10mg	≥98%	in stock	$38.00	$27.00
25mg	>98.0%(T)(HPLC)	in stock	$59.00	$42.00
100mg	99%(HPLC)	in stock	$220.00	$154.00
250mg	>98.0%(T)(HPLC)	in stock	$341.00	$239.00

Description

• Catalog Number: AA26931
• Chemical Name: Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-
• CAS Number: 123663-49-0
• Molecular Formula: C17H14N2O6S
• Molecular Weight: 374.3679
• MDL Number: MFCD00882374
• SMILES: O=CNc1coc2c(c1=O)cc(c(c2)NS(=O)(=O)C)Oc1ccccc1

Computed Properties

• Complexity: 665
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5
• XLogP3: 1.4

Literature

• Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis.

  Molecular immunology 20180101

• Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential.

  The Journal of biological chemistry 20161216

• A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.

  Journal of immunology (Baltimore, Md. : 1950) 20131115

• Iguratimod: a new disease-modifying antirheumatic drug.

  Drugs of today (Barcelona, Spain : 1998) 20120901

• Autoimmune diseases: MIF as a therapeutic target.

  Expert opinion on therapeutic targets 20100301

• Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.

  Chinese medical journal 20080405

• T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis.

  Arthritis research & therapy 20080101

• [Disease modifying anti-rheumatic drugs (DMARDs): an overview].

  Nihon rinsho. Japanese journal of clinical medicine 20050101

• A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo.

  Biochemical and biophysical research communications 20021220

• An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20020401